Your browser doesn't support javascript.
Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers.
Levine, Myron M; Abdullah, Salim; Arabi, Yaseen M; Darko, Delese Mimi; Durbin, Anna P; Estrada, Vicente; Jamrozik, Euzebiusz; Kremsner, Peter G; Lagos, Rosanna; Pitisuttithum, Punnee; Plotkin, Stanley A; Sauerwein, Robert; Shi, Sheng-Li; Sommerfelt, Halvor; Subbarao, Kanta; Treanor, John J; Vrati, Sudhanshu; King, Deborah; Balasingam, Shobana; Weller, Charlie; Aguilar, Anastazia Older; Cassetti, M Cristina; Krause, Philip R; Restrepo, Ana Maria Henao.
  • Levine MM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Abdullah S; Ifakara Health Institute (IHI), Ifakara, Tanzania.
  • Arabi YM; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia.
  • Darko DM; CEO, FDA, Cantonments, Accra, Ghana.
  • Durbin AP; Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Estrada V; Medical School, Complutense University, Hospital Clínico San Carlos, Madrid, Spain.
  • Jamrozik E; Monash Bioethics Centre, Monash University, Victoria, Australia.
  • Kremsner PG; Institut für Tropenmedizin, Universitätsklinikum Tübingen, Germany.
  • Lagos R; Centre de Recherches Médicales de Lambaréné, Gabon.
  • Pitisuttithum P; Centro para Vacunas en Desarrollo (CVD-Chile), Santiago, Chile.
  • Plotkin SA; Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Sauerwein R; Department of Pediatrics, University of Pennsylvania, Doylestown, Pennsylvania, USA.
  • Shi SL; Medical Parasitology Department, Radboud University, Nijmegen, The Netherlands.
  • Sommerfelt H; Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Wuhan, China.
  • Subbarao K; Centre for Intervention Science in Maternal and Child Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, and Norwegian Institute of Public Health, Oslo, Norway.
  • Treanor JJ; WHO Collaborating Centre for Reference and Research on Influenza and Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute, Melbourne, Australia.
  • Vrati S; Infectious Diseases Division, University of Rochester Medical Center, Rochester, New York, USA.
  • King D; Regional Centre for Biotechnology, Haryana (NCR Delhi), India.
  • Balasingam S; Vaccines Priority Area, Wellcome Trust, London, United Kingdom.
  • Weller C; Vaccines, Wellcome Trust, London, United Kingdom.
  • Aguilar AO; Vaccines Programme, Wellcome Trust, London, United Kingdom.
  • Cassetti MC; Global Health Discovery & Translational Sciences, Bill & Melinda Gates Foundation, Seattle, Washington, USA.
  • Krause PR; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
  • Restrepo AMH; Office of Vaccines Research and Review, CEBR, FDA, Silver Spring, Maryland, USA.
Clin Infect Dis ; 72(11): 2035-2041, 2021 06 01.
Article in English | MEDLINE | ID: covidwho-1249280
ABSTRACT
WHO convened an Advisory Group (AG) to consider the feasibility, potential value, and limitations of establishing a closely-monitored challenge model of experimental severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) in healthy adult volunteers. The AG included experts in design, establishment, and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (the potential of SARS-CoV-2 to cause severe/fatal illness, its high transmissibility, and lack of a "rescue treatment" to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Adult / Aged / Humans / Young adult Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Adult / Aged / Humans / Young adult Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid